Innate Pharma SA
F:IDDA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Innate Pharma SA
F:IDDA
|
FR |
Intrinsic Value
The intrinsic value of 
Innate Pharma SA (IDDA) under the Base Case is 0.68 EUR per share.
Compared with the current market price of 1.28 EUR, the stock appears
Overvalued by 47% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Innate Pharma Does
Innate Pharma is a French biotechnology company that develops cancer treatments based on the immune system, especially therapies that use natural killer, or NK, cells and antibodies. It does not make broad consumer products; it builds drug candidates and advances them through research, clinical testing, and partnerships with larger drugmakers.
- Headquarters
- France FR
- Employees
- 163
- IPO date
- Oct 31, 2006
Earnings Waterfall
Innate Pharma SA
The intrinsic value for Innate Pharma SA (IDDA) under the Base Case is 0.68 EUR.
Compared with the current market price of 1.28 EUR, the stock appears Overvalued by 47% .